At one time, atherosclerosis was thought to be a simple lipid storage disease. However, it is now recognized as a chronic and progressive inflammation of the arterial wall. Gene deletion experiments in murine models of atherosclerosis that reduce the inflammatory process also reduce disease severity. Identifying the initiators and mediators of that inflammation can provide promising avenues for prevention or therapy. Two prominent risk factors, hyperlipidaemia and infectious disease, point to innate immune mechanisms as potential contributors to proatherogenic inflammation. The TLRs (Toll-like receptors), pro-inflammatory sensors of pathogens, are potential links between inflammation, infectious disease and atherosclerosis. A mechanism for hyperlipidaemic initiation of sterile inflammation can be postulated because oxidized lipoproteins or their component oxidized lipids have been identified as TLR ligands. Moreover, infectious agents are correlated with atherosclerosis risk. We have identified a role for TLR2 in atherosclerosis in mice deficient in low-density lipoprotein receptor. We observed that proatherogenic TLR2 responses to unknown endogenous or unknown endemic exogenous agonists are mediated by non-BMDC (bone-marrow-derived cells), which can include endothelial cells. In contrast, the proatherogenic TLR2 responses to the defined synthetic exogenous agonist Pam3 CSK4 are mediated at least in part by BMDC, which can include lymphocytes, monocytes/macrophages and dendritic cells. TLR2-mediated cell activation in response to endogenous and exogenous agents is proatherogenic in hyperlipidaemic mice.
Atherosclerosis was once thought to be a simple lipid storage disease that caused pathology by arterial obstruction. Atherosclerosis certainly leads to arterial obstruction but not simply by accumulation of lipid. It is now clear that atherosclerotic lesions are the foci of vessel wall inflammation [1] [2] [3] [4] . Lesions begin very early in life as fatty streaks and progress to pathological lesions driven by the influence of both genetic and lifestyle insults. The final obstructive event is likely to be a sudden thrombotic event rather than a slow, inexorable constriction by accumulation of lipid. During a lifetime that will elapse between fatty streak formation and overt disease, there will be many events that will precipitate lesion progression. Genetic diseases, notably hypercholesterolaemias, lead to very severe disease. Lifestyle choices, which include smoking, obesity and excessive quiescence, can make significant contributions to disease progression, as do hypertension and diabetes. Finally, inflammatory diseases anywhere in the body, ranging from periodontitis to autoimmune disease, have an exacerbating influence as well [5] [6] [7] [8] . However, the factors that promote atherosclerotic lesion progression do not do so uniformly throughout the arterial tree. Lesions form only in arteries at sites of disturbed flow [9] . Such sites are at vessel bifurcations and at the lesser curvature of the aortic arch. Interestingly, these sites display an inflamed phenotype even in the absence of any of the exacerbating disease factors, Key words: agonist, atherosclerosis, cholesterol, endothelial cell, macrophage, Toll-like receptor (TLR). Abbreviations used: ApoE, apolipoprotein E; BMDC, bone-marrow-derived cells; LDLr, lowdensity lipoprotein receptor; MyD88, myeloid differentiation factor 88; Pam3, Pam3 CSK4; TLR2, Toll-like receptor 2. 1 To whom correspondence should be addressed (email lcurtiss@scripps.edu).
and this is due to the altered flow patterns and the endothelial response to disturbed flow [10] [11] [12] .
If inflammation is the hallmark of the disease, then studying the role of TLRs (Toll-like receptors) in atherosclerosis is reasonable. TLRs are initiators of inflammation driven by both endogenous (sterile tissue insults) and exogenous (pathogens) agonists [13, 14] . Probably, given the vicissitudes of daily life, TLRs normally initiate inflammatory responses every day by both types of agonist. Most of these agonists are beneficial because they promote healing and antipathogenic responses, not to mention scientific meetings! But occasionally TLR-mediated responses go awry and cause pathology. Atherosclerosis is one of these pathological events, although TLRs are by no means the only cause or promoter of this arterial disease.
Our laboratory studies TLRs and atherosclerosis in C57Bl/6J mice. There are two C57Bl/6J models in common use, each involving a single gene deletion that results in increased levels of plasma cholesterol. Even when C57Bl/6J wild-type mice are fed a high-fat, high-cholesterol diet, they do not develop atherosclerosis because they do not become hypercholesterolaemic. A popular model uses mice deficient in the gene encoding the LDLr (low-density lipoprotein receptor), a cellular gene whose lack causes human familial hypercholesterolaemia and whose discovery and study won the Nobel Prize for Michael Brown and Joe Goldstein [15] . LDLr deficiency leads to hypercholesterolaemia because synthesis and dietary intake of cholesterol continues but its clearance from the plasma for catabolism by the liver is compromised. This excess plasma cholesterol accumulates in the intima of the arteries in foam cells and leads to lesion development [16] . The other common model for the study of murine atherosclerosis is the ApoE (apolipoprotein E) −/− mouse [17] . ApoE deficiency leads to atherosclerotic lesion development because its absence causes massive accumulation of triacylglycerol-rich lipoproteins in the plasma. For study of TLRs in atherosclerosis, we examined the LDLr −/− mouse exclusively [18, 19] . The reason for this is a disadvantage of the ApoE model. BMDC (bone-marrow-derived cells) synthesize and secrete significant quantities of ApoE. Thus transplantation of BMDC into ApoE −/− mice from ApoEexpressing mice reverses the ApoE deficiency phenotype of the recipient mouse [20] . However, transplanting bone marrow from an LDLr-expressing mouse does not reverse the plasma cholesterol phenotype of the host mouse [21] . The utility of these BMDC chimaeras will be discussed below.
In addition to our experiments, reviewed below, others have studied disease development in mice deficient in MyD88 (mycloid differentiation factor 88), TLR4 and CD14 [22, 23] . These studies showed that TLR4 and MyD88 deficiency retards disease development, whereas CD14 deficiency has no effect on disease development.
We focused on TLR2 because our in vitro experiments with cultured human coronary artery endothelial cells showed that cells exposed to an approximation of the disturbed flow conditions prevalent at sites of lesion development up-regulated responsiveness to TLR2 agonists [24] . This was due to an enhanced expression of TLR2 in response to disturbed flow. We did not observe that disturbed flow enhances responses to TLR4 or TNFα (tumour necrosis factor α) receptor ligands.
Initial results with double knockout LDLr −/− TLR2 −/− mice showed that whole body deficiency of TLR2 results in decreased lesion burden after 10 or 14 weeks of consuming a high-fat diet [25] . Thus the existence of a functional TLR2 promotes disease. In these experiments, no agonist of TLR2 was deliberately administered; thus we refer to the TLR2 agonists involved in this disease as endogenous agonists. It should be understood that these mice are healthy, but not germ-free. Thus the endogenous agonist may come from the genome of commensal organisms or from the genome of the mouse itself [14] . However, Wright et al. [26] showed some years ago that germ-free (notobiotic) mice did not develop disease, and thus we favour the hypothesis that endogenous TLR2 agonists are generated by the mouse itself. Others had shown that administration of LPS (lipopolysaccharide), an exogenous TLR4 agonist, promoted disease in rabbits and mice [27, 28] . In additional experiments, we showed that administration of Pam3 (Pam3 CSK4; Invivogen) promoted additional dramatic disease in the hyperlipidaemic LDLr −/− mice and that this was abrogated in LDLr −/− TLR2 −/− mice [25] . Thus both endogenous and exogenous agonists promote disease by activation of TLR2 signalling, and TLR2 is one route for both genetic and inflammatory pathways to atherosclerotic disease. Our observations with LDLr −/− mice were recently confirmed in ApoE −/− mice [29] . Using bone marrow transplantation, we were able to determine whether TLR expressed by BMDC on non-BMDC was disease-promoting. To our surprise, we found that both BMDC and non-BMDC were disease-promoting, but which cells were involved depended on the source of the agonist [25] . Non-BMDC-expressed TLR2 was sufficient to promote disease in response to the unknown endogenous agonist(s), whereas BMDC-expressed TLR2 was sufficient to promote disease only in response to exogenous agonists. Given the known role of endothelial cells in regulating transport into the intima, it seems likely that the cells responding to TLR2 agonist(s) are endothelial cells. Similarly, given the known relevance of monocytes/macrophages in responding to exogenous TLR2 agonists, it seems likely that these are the cells driving lesion development in response to the exogenous agonists. However, given these assumptions, it is not yet understood why macrophage TLR2 does not exacerbate disease in response to endogenous agonist(s) and why endothelial cell TLR2 does not intensify disease progression in response to exogenous agonists.
Using confocal microscopy of murine aortic arch tissue fragments, we have examined the distribution of TLR2 expression on the luminal face of the aortic arch. These images show very little TLR2 expression in either wild-type C57Bl/6J mice or in LDLr −/− mice fed a chow diet. However, this minimal TLR2 expression is only found in the lesser curvature region. Within 1-2 weeks of feeding LDLr −/− mice a high-fat diet, TLR2 expression is significantly increased in the lesser curvature region of the aorta. Moreover, it is expressed only by the endothelial cells and not by the myeloid cells within the intima just below the endothelium. Why these bone-marrow-derived myeloid cells are not expressing TLR2 is open to conjecture. Brunn et al. [30] have shown that TLR4 signalling is strongly inhibited by extracellular matrix components. Something similar could be happening with TLR2. Certainly, the intimal macrophages are residing in a space with lots of extracellular matrix material. Further, when one studies which cells are accumulating lipid at these early stages of lesion development, it is predominately the CD31-expressing endothelial cells and not the CD68-expressing myeloid cells.
What are the endogenous TLR2 agonists to which endothelial cells are sensitive? Given the important role of oxidized lipoproteins in lesion development, it is tempting to point to these moieties, but no oxidized lipoprotein has yet been shown to be a TLR2 agonist. Other possibilities include HMGB1 (high-mobility group B1), biglycan, hyaluronic acid fragments, necrotic cells and SAA (serum amyloid A) [31] [32] [33] [34] [35] [36] . All of these have been shown to be TLR2 agonists in vitro. We hypothesize that these agonists, and possibly others such as AGEs (advanced glycation end-products) [37] , may activate endothelial cells at lesion sites through TLR2 because it is only the endothelial cells at lesion-prone sites that express TLR2.
If the aortic myeloid cells do not express TLR2, how is it that exogenous agonists such as Pam3 promote lesion development [18] ? There are at least two possibilities to consider. First, the exogenously administered agonist stimulates a mediator response, which drives TLR2 expression on myeloid cells within the intima of the arterial wall. Alternatively, the exogenous agonist stimulates mediators that promote site-specific endothelial cell activation, which serves to promote recruitment of monocytes that then enter the lesion and become activated by other means. These two hypotheses should not be difficult to distinguish experimentally.
There are abundant data to indicate that inflammatory processes play a pivotal role throughout the development of atherosclerosis. The idea that TLRs participate in these processes is now clear, although only two, TLR2 and TLR4, have been studied in any detail. Multiple cell types within the atheroma, including endothelial cells, dendritic cells, macrophages, vascular smooth-muscle cells and perhaps even adventitial fibroblasts, could participate in this arterial inflammatory response. TLR2 does not cause atherosclerosis, but it certainly participates in its development. Given that the endogenous agonists, which drive atherosclerotic disease, are likely to be involved in normal surveillance and homoeostatic processes, atherosclerosis can be considered as an innate immune disorder that is exacerbated by chronic inflammation.
